CA2453062C - Group b streptococcus bvh-a5 antigens and corresponding dna fragments - Google Patents

Group b streptococcus bvh-a5 antigens and corresponding dna fragments Download PDF

Info

Publication number
CA2453062C
CA2453062C CA2453062A CA2453062A CA2453062C CA 2453062 C CA2453062 C CA 2453062C CA 2453062 A CA2453062 A CA 2453062A CA 2453062 A CA2453062 A CA 2453062A CA 2453062 C CA2453062 C CA 2453062C
Authority
CA
Canada
Prior art keywords
amino acid
polypeptide
seq
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2453062A
Other languages
English (en)
French (fr)
Other versions
CA2453062A1 (en
Inventor
Denis Martin
Stephane Rioux
Bernard R. Brodeur
Josee Hamel
Martine Boyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
ID Biomedical Corp of Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ID Biomedical Corp of Quebec filed Critical ID Biomedical Corp of Quebec
Publication of CA2453062A1 publication Critical patent/CA2453062A1/en
Application granted granted Critical
Publication of CA2453062C publication Critical patent/CA2453062C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2453062A 2001-07-06 2002-07-05 Group b streptococcus bvh-a5 antigens and corresponding dna fragments Expired - Fee Related CA2453062C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30310101P 2001-07-06 2001-07-06
US60/303,101 2001-07-06
PCT/CA2002/001019 WO2003004650A2 (en) 2001-07-06 2002-07-05 Group b streptococcus antigens and corresponding dna fragments

Publications (2)

Publication Number Publication Date
CA2453062A1 CA2453062A1 (en) 2003-01-16
CA2453062C true CA2453062C (en) 2013-04-02

Family

ID=23170538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2453062A Expired - Fee Related CA2453062C (en) 2001-07-06 2002-07-05 Group b streptococcus bvh-a5 antigens and corresponding dna fragments

Country Status (10)

Country Link
US (2) US7393536B2 (enExample)
EP (1) EP1407023B1 (enExample)
JP (2) JP4374245B2 (enExample)
AT (1) ATE452191T1 (enExample)
AU (1) AU2002317107B2 (enExample)
BR (1) BR0210875A (enExample)
CA (1) CA2453062C (enExample)
DE (1) DE60234772D1 (enExample)
ES (1) ES2337773T3 (enExample)
WO (1) WO2003004650A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939087B2 (en) * 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
EP1343895B1 (en) * 2000-12-21 2008-06-18 ID Biomedical Corporation Streptococcus pyogenes antigens and corresponding dna fragments
JP2005514052A (ja) * 2001-12-21 2005-05-19 チルドレンズ ホスピタル アンド レジオナル メディカル センター Ｂ群連鎖球菌の新規の細胞表面プロテアーゼの使用
WO2012138470A2 (en) 2011-04-04 2012-10-11 Intelligent Medical Devices, Inc. Optimized oligonucleotides and methods of using same for the detection, isolation, amplification, quantitation, monitoring, screening, and sequencing of group b streptococcus
KR101675382B1 (ko) 2015-04-07 2016-11-14 (주) 씨에스코리아 황토보드 제조방법 및 그에 의해 제조되는 황토보드

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618813B1 (en) 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigen of hybrid m protein and carrier for group a streptococcal vaccine
DE69836744T2 (de) 1997-09-12 2007-10-04 University Of Tennessee Research Foundation, Knoxville Gruppe a streptokokken-impfstoff
PL205041B1 (pl) 1998-12-23 2010-03-31 Id Biomedical Corp Izolowany polinukleotyd, wektor zawierający izolowany polinukleotyd, komórka gospodarza transfekowana lub transformowana za pomocą tego wektora, sposób wytwarzania polipeptydu kodowanego przez izolowany polinukleotyd, izolowany polipeptyd, chimeryczny polipeptyd, kompozycja do szczepionek zawierająca polipeptyd oraz jej zastosowanie w leczeniu lub zapobieganiu zakażeniu osobnika paciorkowcem
GB9921125D0 (en) 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
US7939087B2 (en) * 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
FR2824074A1 (fr) 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens

Also Published As

Publication number Publication date
CA2453062A1 (en) 2003-01-16
US7740870B2 (en) 2010-06-22
JP5194199B2 (ja) 2013-05-08
BR0210875A (pt) 2004-06-22
US20040242844A1 (en) 2004-12-02
WO2003004650A2 (en) 2003-01-16
JP2009240316A (ja) 2009-10-22
JP2005501534A (ja) 2005-01-20
DE60234772D1 (de) 2010-01-28
JP4374245B2 (ja) 2009-12-02
AU2002317107B2 (en) 2008-06-12
EP1407023B1 (en) 2009-12-16
US7393536B2 (en) 2008-07-01
ES2337773T3 (es) 2010-04-29
ATE452191T1 (de) 2010-01-15
EP1407023A2 (en) 2004-04-14
US20090042794A1 (en) 2009-02-12
WO2003004650A3 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
US9340586B2 (en) Streptococcus pyogenes antigens and corresponding DNA fragments
US7740870B2 (en) Group B Streptococcus antigens and corresponding DNA fragments
EP1472353B1 (en) Group b streptococcus antigen
EP1362106B1 (en) Streptococcus pyogenes polypeptides and corresponding dna fragments
AU2002317107A1 (en) Group B streptococcus antigens and corresponding DNA fragments
EP1325133B1 (en) Bvh-a2 and bvh-a3 antigens of group b streptococcus
US20040171113A1 (en) Antigens of group b streptococcus and corresponding dna fragments
US20070110763A1 (en) Polypeptides of streptococcus pyogenes
WO2004007725A9 (en) Polypeptide of streptococcus pyogenes
WO2002079475A2 (en) Streptococcus pyogenes antigens and corresponding dna fragments

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190705